Last quarter (Q ), Forma Therapeutics Holdings's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Forma Therapeutics Holdings's net income was $-52.58M. See Forma Therapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 0.00	$ 0.00	$ 100.56M	$ 164.09M
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 191.13M	$ 173.99M	$ 124.15M	$ 135.72M	$ 154.40M
Operating Income	$ -191.13M	$ -173.99M	$ -124.15M	$ -35.16M	$ 9.69M
Net Non Operating Interest Income Expense	$ 1.39M	$ 1.05M	$ 3.43M	$ 2.85M	$ 3.69M
Other Income Expense	$ -390.00K	$ 122.00K	$ 20.59M	$ -4.33M	$ 482.00K
Pretax Income	$ -190.13M	$ -172.81M	$ -100.13M	$ -36.64M	$ 13.86M
Tax Provision	$ 28.00K	$ 154.00K	$ -29.72M	$ -1.85M	$ 8.57M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -190.16M	$ -172.96M	$ -74.15M	$ -52.75M	$ 93.00K
Basic EPS	$ -4.00	$ -3.65	$ -3.22	$ -3.15	$ <0.01
Diluted EPS	$ -4.00	$ -3.65	$ -3.22	$ -3.15	$ -0.03
Basic Average Shares	$ 190.12M	$ 47.35M	$ 23.06M	$ 11.37M	$ 11.37M
Diluted Average Shares	$ 190.12M	$ 47.35M	$ 23.06M	$ 11.37M	$ 11.37M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 191.13M	$ 173.99M	$ 124.15M	$ 135.72M	$ 154.40M
Net Income From Continuing And Discontinued Operation	$ -190.16M	$ -172.96M	$ -70.41M	$ -34.79M	$ 5.29M
Normalized Income	$ -189.95M	$ -172.96M	$ -86.76M	$ -29.77M	$ 5.29M
Interest Expense	-	-	-	-	-
EBIT	$ -191.13M	$ -173.99M	$ -124.15M	$ -35.16M	$ 9.69M
EBITDA	$ -188.56M	$ -172.42M	$ -122.87M	$ -32.49M	$ 13.22M

Currency in USD

Forma Therapeutics Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing